Anzeige
Mehr »
Mittwoch, 07.01.2026 - Börsentäglich über 12.000 News
Wie ein junger Batterie-Spezialist plötzlich zum unverzichtbaren Partner wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Investing.com

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
DiSunrun stock gains as Oppenheimer praises new joint venture strategy
DiMarvell stock to acquire XConn for $540M, Raymond James reiterates Strong Buy
DiNvidia stock holds Buy rating at Stifel on autonomous vehicle potential
DiTruist Securities raises Ideaya Biosciences stock price target to $60
DiTruist Securities raises Lucky Strike Entertainment price target to $12
DiTruist Securities reiterates Hold rating on Leggett and Platt stock
DiO-I Glass stock price target raised to $21 from $17 at Truist Securities
DiSpartan Delta stock price target raised to C$9 by BMO on Duvernay growth
DiBlackRock discloses 6.72% stake in Avadel Pharmaceuticals
DiBMO Capital reiterates TC Energy stock rating, adds to Top 3 Best Ideas
DiAmundi Physical Gold ETC issues 879,000 new securities in latest tranche
DiPrincess cruises expands northern Europe program for 2027
DiE.F. Hutton raises $5.5 million for iSpecimen in private placement
DiHackett Group launches AI XPLR' 5.0 for enterprise AI scaling
DiNeedham maintains Hold rating on STAAR Surgical stock after failed acquisition
DiLiberty Energy stock gains as UBS reiterates Buy rating on data center deal
DiSTAAR Surgical stock rating reiterated as Neutral by BTIG
DiCME Group stock price target maintained at $280 by UBS
DiValero Energy stock rating reiterated at Buy by UBS on refining strength
DiPhillips 66 stock: UBS reiterates Buy rating as company acquires UK refinery assets
DiTD Cowen sees broker stocks as attractive entry point despite P&C pricing slowdown
DiCraig-Hallum downgrades CareDx stock rating to Hold from Buy
DiBaird raises Alumis stock price target to $35 on strong psoriasis trial data
DiUBS reiterates Neutral rating on Crocs stock, maintains $85 price target
DiAmbarella launches developer zone to speed up edge AI application creation